As an automotive company in constant evolution, Renault Group is profoundly redefining the design of its vehicles, by rethinking how they are conceived. In an exclusive series entitled “Design Talks”, ...

Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve ...

-- ( BUSINESS WIRE )--Keysight Technologies, Inc. (NYSE: KEYS): ...

Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting ...

New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences Data showed ability of INO-3107 to induce an ...

High dose TSHA-102 was generally well tolerated with no SAEs or DLTs in two adolescent/adult patients and one <a target=_blank href= ...

Inovio Pharmaceuticals (NASDAQ: INO) Q3 2024 Earnings Call Nov 14, 2024, 4:30 p.m. ET ...

Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patien ...

MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the third quarter ended September 30, ...

Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good afternoon, and welcome to Fractyl Health’s Third Quarter Financial Results and Business Updates Call. As a reminder, this conference ...

RJVA-002 is a locally administered AAV9 viral vector that expresses human GIP and GLP-1 hormones ... was $19.0 million for the quarter ended September 30, 2024, compared to $9.4 million for the same ...

Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, USA ...